HumacyteHUMA
NASDAQBiotech
No cached AI snapshot yet for HUMA.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
184 employees222.02M shares outstandinglisted 2021-08-27
Next earnings ~May 5, 2026
About Humacyte
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Latest News
Showing market-wide stock news
USD/JPY Price Forecast: Retreats from 155.50 with Fed’s policy in focus
Equities: Fed focus and energy shock – Deutsche Bank
Euro makes a run at 1.15, December hike groundwork is set to continue
Factbox-Major brokerages’ forecasts for S&P 500 index in 2026
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
Related Stocksin Biotech
Ready to see the live AI view on HUMA?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing HUMA side-by-side with live signals.